16 articles with Affinivax
Affinivax, Inc., a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ platform, announced that Kara Bickham, MD, has joined the company as Chief Medical Officer.
The vaccine candidate ASP3772 generated an antibody response to each of the 24 polysaccharides in its makeup and antibody response to the two conserved pneumococcal proteins.
Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae
Affinivax, Inc. and Astellas Pharma Inc. announced results from the Phase 2 clinical trial of ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae.
Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform , today announced that Elizabeth Radcliffe has joined the company as Chief Financial Officer.
3/10/2021Money flows into life sciences companies on a daily basis. Here’s who’s celebrating this week.
Affinivax Announces Award from CARB-X for up to $22 Million to Advance its Staphylococcus aureus MAPS™ Vaccine Candidate into Clinical Trials
Affinivax Announces Award from CARB-X for up to $22 Million to Advance its Staphylococcus aureus MAPS™ Vaccine Candidate into Clinical Trials Novel MAPS™ vaccine is designed to induce both a B-cell and T-cell protective immune response to multiple, highly conserved staphylococcal protein antigens
Affinivax Announces $226 Million Series C Financing to Advance Its Pipeline of Novel MAPS™ Vaccines Targeting Infectious Diseases
Lead pneumococcal vaccine in clinical development offers potential for broader protection than any vaccine on the market or in clinical trials today
Affinivax, Inc. ("Affinivax"), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, today announced that Steven Brugger, president and CEO of Affinivax, will deliver a company presentation at the 39 th Annual J.P. Morgan Healthcare Confer
Affinivax Announces $120 Million Series B Financing to Advance Pipeline of Novel MAPS Vaccines and Immunotherapies
Lead pneumococcal vaccine currently in clinical trials designed to provide broadest protection
Cambridge, Mass.-based Affinivax completed a $120 million Series B financing round that will be used to advance its vaccine and immunotherapy candidates.
4/19/2019Biotech, pharma and life science companies make appointments to leadership roles, with additions at Cerevance, Obsidian, KSQ, Lygos, and more.
Frank Malinoski, MD, PhD, joins Affinivax as Senior Vice President of Clinical Development and Regulatory Affairs
Industry veteran brings over 30 years of development and commercial experience across multiple vaccine and immunotherapy products
Affinivax, Inc. Announces Initiation of Phase 1/2 Clinical Study of ASP3772, Its Novel Pneumococcal MAPS Vaccine, in Collaboration with Astellas
Clinical study will evaluate safety, tolerability, and immunogenicity in adults
Once again, Amgen is accepting submissions for the 2018 Amgen-LabCentral Golden Ticket competition.
Affinivax Secures Additional Funding To Advance Its Novel Pneumococcal Vaccine Towards Clinical Trials